Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Boston Beer Company Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Boston Beer Company Inc trades at $176.75 (market cap $1.82B). The key difference: Boston Beer Company Inc is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Boston Beer Company Inc for 60 Days on average.
| MRVI | SAM | |
|---|---|---|
Market Cap | $972.90M | $1.82B |
Volume | 4,325,710 | 202,975 |
Sector | Health | Consumer Staples |
52-Week High | $9.00 | $260.05 |
52-Week Low | $2.83 | $161.08 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $1.08B | $1.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SAM trades at $178.14, up 1.74% today, near resistance at $178. The stock shows a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, 2025 revenue held at $1.96B with net income improving to $108M, yet 2026 guidance projects a net loss. The company is expanding its brand portfolio with new products and marketing initiatives to counter volume declines.
Outlook: SAM faces near-term headwinds from projected 2026 losses and competitive pressure, but brand investments and innovation provide growth avenues. Risks include execution challenges and weak consumer demand. The consensus price target of $204.44 implies potential upside, supported by a debt-free balance sheet, but investor sentiment remains cautious amid earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
